The emerging role of antibody-drug conjugates in urothelial carcinoma Review
| Authors: | Lattanzi, M.; Rosenberg, J. E. |
| Review Title: | The emerging role of antibody-drug conjugates in urothelial carcinoma |
| Abstract: | Introduction: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma. Antibody-drug conjugates represent a new therapeutic modality in urothelial cancer; and beyond nectin-4, agents targeting Trop-2, HER2, and EpCAM are also in clinical development. Areas covered: This review outlines the biologic rationale and the clinical development of novel antibody-drug conjugates for the treatment of urothelial cancer across the spectrum of disease from non-muscle-invasive bladder cancer through treatment-refractory metastatic disease. Expert opinion: The high response rates observed with enfortumab vedotin–both as monotherapy and in combination with checkpoint blockade immunotherapy–suggest this and other antibody-drug conjugates may have efficacy similar to or even exceeding that of traditional cytotoxic chemotherapy. Ongoing clinical development of antibody-drug conjugates in urothelial cancer will address the optimal combination or sequencing strategy with anti-PD-1/L1 immunotherapy and platinum-based chemotherapy. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | cancer chemotherapy; treatment response; unclassified drug; fatigue; neutropenia; review; cisplatin; diarrhea; drug efficacy; drug approval; gemcitabine; paclitaxel; rituximab; carboplatin; cancer immunotherapy; sensory neuropathy; anemia; bone marrow suppression; peripheral neuropathy; bendamustine; cytotoxicity; drug design; bladder cancer; acute lymphoblastic leukemia; hodgkin disease; docetaxel; febrile neutropenia; hyperglycemia; peripheral t cell lymphoma; immunotherapy; patient safety; alopecia; transitional cell carcinoma; her2; vinflunine; gemtuzumab ozogamicin; urothelial; programmed death 1 ligand 1; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); inotuzumab ozogamicin; anaplastic large cell lymphoma; acute myeloid leukemia; trastuzumab emtansine; diffuse large b cell lymphoma; antibody-drug conjugate; non muscle invasive bladder cancer; brentuximab vedotin; human epidermal growth factor receptor 2 positive breast cancer; nivolumab; human; pembrolizumab; bladder irritation; durvalumab; polatuzumab vedotin; atezolizumab; antibody drug conjugate; nectin-4; enfortumab vedotin; oportuzumab monatox; sacituzumab govitecan; trastuzumab deruxtecan; rc 48 |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 20 |
| Issue: | 7 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2020-07-01 |
| Start Page: | 551 |
| End Page: | 561 |
| Language: | English |
| DOI: | 10.1080/14737140.2020.1782201 |
| PUBMED: | 32552213 |
| PROVIDER: | scopus |
| PMCID: | PMC7545404 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 August 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work